Nirav Shah
-
- MicroRNA in disease regulation 5
- Cancer-related molecular mechanisms research 4
- Pharmaceutical Science top 10%
- Rehabilitation top 10%
- Animal Science and Zoology top 10%
-
- Virus-based gene therapy research 2
-
- Circular RNAs in diseases 4
- Mitochondrial Function and Pathology 2
-
- COVID-19 Clinical Research Studies 3
- SARS-CoV-2 and COVID-19 Research 2
-
- Inhalation and Respiratory Drug Delivery 2
- Co-authors
- Vivek P. ChavdaMegan Moerdyk‐SchauweckerPinku MukherjeeEric HastieValery Z. GrdzelishviliNam Y. LeeChristopher C. PanHexin Chen
- Partner nations
- United StatesIndiaUnited Kingdom
In The Last Decade
Nirav Shah
22 papers receiving 569 citations
Peers
Comparison fields: 5 of 90
- Cancer Research 137
- Pharmaceutical Science 33
- Rehabilitation 37
- Animal Science and Zoology 44
- Genetics 117
Countries citing papers authored by Nirav Shah
This map shows the geographic impact of Nirav Shah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nirav Shah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nirav Shah more than expected).
Fields of papers citing papers by Nirav Shah
This network shows the impact of papers produced by Nirav Shah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nirav Shah. The network helps show where Nirav Shah may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Nirav Shah, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 10 | |
| 2 | 2022 | 32 | |
| 3 | 2022 | 1 | |
| 4 | 2022 | 5 | |
| 5 | 2021 | 38 | |
| 6 | 2021 | 32 | |
| 7 | 2018 | 17 | |
| 8 | 2018 | 46 | |
| 9 | 2017 | 1 | |
| 10 | 2017 | 1 | |
| 11 | 2016 | 54 | |
| 12 | 2016 | 43 | |
| 13 | 2016 | 2 | |
| 14 | 2015 | 2 | |
| 15 | 2014 | 58 | |
| 16 | 2014 | 17 | |
| 17 | 2013 | 23 | |
| 18 | 2012 | 97 | |
| 19 | 1995 | 53 | |
| 20 | 1993 | 3 |
About Nirav Shah
Nirav Shah is a scholar working on Cancer Research, Pharmaceutical Science and Animal Science and Zoology, having authored 22 papers that have together received 587 indexed citations. Recurring topics across this work include MicroRNA in disease regulation (5 papers), Circular RNAs in diseases (4 papers), Cancer-related molecular mechanisms research (4 papers), COVID-19 Clinical Research Studies (3 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Virus-based gene therapy research (2 papers), Mitochondrial Function and Pathology (2 papers) and Inhalation and Respiratory Drug Delivery (2 papers). The work is most often cited by research in Cancer Research (137 citations), Pharmaceutical Science (33 citations) and Rehabilitation (37 citations). Nirav Shah has collaborated with scholars based in United States, India and United Kingdom. Frequent co-authors include Vivek P. Chavda, Megan Moerdyk‐Schauwecker, Pinku Mukherjee, Eric Hastie, Valery Z. Grdzelishvili, Nam Y. Lee, Christopher C. Pan, Hexin Chen, Normi D. Gajjar and Sanjay Kumar. Their work appears in journals such as Frontiers in Pharmacology, Cancer Research, Journal of Virology, Journal of Drug Delivery Science and Technology and Journal of Pharmaceutical Innovation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.